HOTLINE: Effective May 16, 2022

2013664	**Cystic Fibrosis (*CFTR*) Expanded Variant Panel with Reflex to Sequencing and Reflex to Deletion/Duplication**	**CFVAR COMP**

Specimen Required: Collect: Lavender (K_2EDTA), pink (K_2EDTA).
Specimen Preparation: Transport 5 mL whole blood. (Min: 3 mL)
Storage/Transport Temperature: Refrigerated.
Remarks:
Unacceptable Conditions: Plasma or serum. Specimens collected in sodium heparin, yellow (ACD solution A or B), or lithium heparin tubes. Frozen specimens in glass collection tubes.
Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month

Interpretive Data:
Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: If less than two pathogenic variants are identified by the Cystic Fibrosis (*CFTR*) Expanded Variant Panel, then *CFTR* gene sequencing will be performed. Following sequencing, if less than two pathogenic variants are identified, then *CFTR* deletion/duplication analysis will be performed. Additional charges will apply for each tier performed.

HOTLINE NOTE: There is a clinically significant charting name change associated with this test.
Change the charting name for component 2013682, CF 165 Exp Var. Rfx to Seq Rfx DD, Interp from CF 165 Exp Var. Rfx to Seq Rfx DD, Interp to CF Exp Var Rfx to Seq Rfx DD Interp.